Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kalamazoo, Michigan, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for third quarter of fiscal year 2023 on Thursday, November 2, 2023.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's third quarter of fiscal year 2023, that ended September 30, 2023.

Stryker to announce financial results for its third quarter of fiscal year 2023

Over 1 million Triathlon Cementless Knees implanted globally MAHWAH, N.J. , Sept. 21, 2023 /PRNewswire/ -- Stryker (NYSE: SYK), one of the world's leading medical technology companies, continues its year of milestones celebration with the 10th anniversary of the Triathlon Tritanium baseplate.

Stryker's Triathlon Tritanium Baseplate marks a decade of positive patient impact

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker launched its PROstep® MIS Lapidus, a new minimally invasive surgical option for treating patients with bunions.

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.

Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes

Stryker's 1788 camera platform brings enhanced technology to the operating room – including a wider color gamut, more vivid white light and new fluorescence imaging capabilities SAN JOSE, California, USA, Sept. 14, 2023 /PRNewswire/ -- Stryker (NYSE: SYK), one of the world's leading medical technology companies, today unveiled the next-generation of minimally invasive surgical cameras: the 1788 platform.

A Clearer Vision of Surgery: Stryker Releases its Next-Generation of Advanced Surgical Cameras

Stryker's (SYK) Pangea systems will boost the company's Trauma business unit following a complete launch. SYK plans to present the new system at the Annual Orthopaedic Trauma Association meeting.

Stryker (SYK) Gets FDA 501k Clearance for Pangea Trauma Systems

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker's Pangea Systems including Femur, Fibula, Tibia, Humerus and Utility have received 510k clearance from the U.S. Food & Drug Administration.

Stryker's Pangea Systems Receive FDA Clearance

Stryker Corporation (NYSE:SYK ) Wells Fargo Securities Healthcare Conference Call September 7, 2023 3:00 PM ET Company Participants Glenn Boehnlein - CFO Jason Beach - VP, IR Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen I'm Larry Biegelsen, the medical device analyst at Wells Fargo and it's my pleasure to host this session with Stryker. From the company, we have Glenn Boehnlein, the CFO; and Jason Beach, the Vice President of Investor Relations.

Stryker Corporation (SYK) Wells Fargo Securities Healthcare Conference (Transcript)

Analysts at Bank of America have upgraded their rating on medical technologies company Stryker Corporation (NYSE:SYK) to ‘Buy' on their belief it is likely to be a top-tier performer in 2024. They also increased their price target on the Kalamazoo, Michigan-based company from US$310 to US$315.

Stryker upgraded to ‘Buy' on 2024 upside potential

Airbnb

Chipotle

AllianceBernstein Hld

American Express

Boston Properties

Cameco

Centene

Domino's Pizza

Con Ed

Lincoln National

Lowe's

Lululemon Athletica

Lamb Weston Hlds

MongoDB

Newell Brands

Paychex

Scotts Miracle-Gro

SoFi Technologies

Toll Brothers

Warner Bros Discovery Inc

Here are some of the tickers on my radar for Tuesday, Sept. 5, taken directly from my reporter's notebook.

Here are 19 stocks Jim Cramer is watching, including Chipotle, LULU and Airbnb

AbbVie

Baxter

Intuitive Surgical

Medtronic

Med tech has been on the skids for no fault of its own. It's not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has normalized.

A Significant Reversal is in Sight for These 5 Med Tech Companies

Stryker's robotic arm technology for knee replacement surgeries positions them as a leader in orthopedic surgeries. The recovery of procedure volumes post-Covid has already contributed to Stryker's organic growth rate. Stryker's Mako robotic technology is a key growth driver and offers a unique value proposition in the market.

Stryker: Procedure Volume Recovery And Mako's Leading Robotic Technology

Stryker's net sales and earnings climbed in the second quarter. The company's seemingly modest payout could have many more years of growth ahead.

Is This MedTech Giant a Buy for Dividend Investors?

Kalamazoo, Michigan, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2023 Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023.

Stryker to participate in the 2023 Wells Fargo Securities Healthcare Conference

Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stryker (SYK) Reports Q2 Earnings: What Key Metrics Have to Say

Today, Stryker Corp ( SYK , Financial) experienced a daily change of 3.27%, with an Earnings Per Share (EPS) of 6.87. The question on the minds of many investors is whether the stock is fairly valued.

Is Stryker Corp (SYK) Fairly Valued? An In-depth Analysis

Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.

Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves

"Scan. Plan. Mako Can." spotlights and differentiates Stryker's Mako SmartRobotics™ for partial knee, total knee and total hip replacement surgery MAHWAH, N.J.

Stryker launches national direct-to-patient marketing campaign

Stryker Corporation (NYSE:SYK ) Q2 2023 Results Conference Call August 3, 2023 4:30 PM ET Company Participants Kevin Lobo - Chair and CEO Glenn Boehnlein - CFO Jason Beach - VP, IR Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Matthew O'Brien - Piper Sandler Ryan Zimmerman - BTIG Shagun Singh - RBC Eric Anderson - TD Cowen Matt Miksic - Barclays Joanne Wuensch - Citibank Rick Wise - Stifel Travis Steed - Bank of America Mike Matson - Needham & Company Richard Newitter - Truist Securities Operator Welcome to the Second Quarter 2023 Stryker Earnings Call. My name is Todd and I will be your operator for today's call.

Stryker Corporation (SYK) Q2 2023 Earnings Call Transcript

Stryker (SYK) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $2.38 per share. This compares to earnings of $2.25 per share a year ago.

Stryker (SYK) Q2 Earnings and Revenues Beat Estimates

Stryker raised its annual profit forecast on Thursday as the medtech company sees strong demand for its medical and surgical devices, aided by a post-pandemic pickup in surgical procedure volumes at hospitals.

Stryker lifts annual profit forecast as demand for its devices picks up

Kalamazoo, Michigan, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2023: Second Quarter Results Reported net sales increased 11.2% to $5.0 billion Organic net sales increased 11.9% Reported operating income margin of 19.3% Adjusted operating income margin (1) increased 60 bps to 24.3% Reported EPS increased 12.2% to $1.93 Adjusted EPS (1) increased 12.9% to $2.54   Second Quarter Net Sales Growth Overview   Reported   Foreign Currency Exchange   Constant Currency   Acquisitions / Divestitures   Organic MedSurg and Neurotechnology         12.2         %           (0.7)        %           12.9         %           —         %           12.9         % Orthopaedics and Spine         9.9                     (0.7)                      10.6                     —                     10.6           Total         11.2         %           (0.7)        %           11.9         %           —         %           11.9         % "We delivered strong organic sales growth in the second quarter as demand for our products remains strong," said Kevin A. Lobo, Chair and CEO.

Stryker reports second quarter 2023 operating results

Kalamazoo, Michigan, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable October 31, 2023 to shareholders of record at the close of business on September 29, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter.

Stryker declares a $0.75 per share quarterly dividend

Abbott Labs

Haemonetics

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. ABT, SYK, ZBH and HAE are well poised to gain from the favorable factors.

4 Medical Product Stocks to Buy Amid Recovering Prospects

Stryker (SYK) launches its Q Guidance system with Cranial Guidance software, offering surgeons a comprehensive planning and guidance solution for complex cranial procedures.

News for Stryker Stock (SYK)